Searchable abstracts of presentations at key conferences in endocrinology

ea0050p267 | Neuroendocrinology and Pituitary | SFEBES2017

11C-methionine PET can aid localisation of the source of ACTH-dependent Cushing’s syndrome in patients with equivocal or negative conventional imaging.

Tobin Jake , White Louisa , Koulouri Olympia , Bashari Waiel , Powlson Andrew , Gillett Daniel , Cheow Heok , Gurnell Mark

Background: Cross-sectional imaging (e.g. CT/MRI) can not always reliably identify the site of ACTH secretion in Cushing’s disease (CD) or the ectopic ACTH syndrome (EAS). We report our experience of localising the source of ACTH-dependent Cushing’s syndrome, using functional imaging with 11C-methionine positron emission tomography (Met-PET).Methods: Forty consecutive patients with: (i) de novo ...

ea0050p267 | Neuroendocrinology and Pituitary | SFEBES2017

11C-methionine PET can aid localisation of the source of ACTH-dependent Cushing’s syndrome in patients with equivocal or negative conventional imaging.

Tobin Jake , White Louisa , Koulouri Olympia , Bashari Waiel , Powlson Andrew , Gillett Daniel , Cheow Heok , Gurnell Mark

Background: Cross-sectional imaging (e.g. CT/MRI) can not always reliably identify the site of ACTH secretion in Cushing’s disease (CD) or the ectopic ACTH syndrome (EAS). We report our experience of localising the source of ACTH-dependent Cushing’s syndrome, using functional imaging with 11C-methionine positron emission tomography (Met-PET).Methods: Forty consecutive patients with: (i) de novo ...

ea0086oc3.5 | Reproductive and Neuroendocrinology | SFEBES2022

Radiomics as a tool for risk stratification of non-functioning pituitary adenomas following primary surgery

MacFarlane James , Gillett Daniel , Koulouri Olympia , Bashari Waiel , Casey Ruth , Gurnell Mark

Background: Existing biomarkers have limited ability to discriminate indolent non-functioning pituitary adenomas (NFPAs) from those with a propensity to recur following primary surgery. Radiomics, the extraction of quantitative data from medical imaging, is increasingly recognised as a tool to augment clinical decision making.Methods: 39 patients who underwent primary trans-sphenoidal surgery for an NFPA between January 2007 and April 2017, were enrolled...

ea0077op2.1 | Adrenal and Cardiovascular | SFEBES2021

A phase 1 clinical trial evaluating the safety and efficacy of up to two administrations of the adrenal PET tracer [18F]CETO in healthy volunteers and patients with primary aldosteronism

Senanayake Russell , Gillett Daniel , Bashari Waiel , MacFarlane James , Hu Lihua , Palma August , Aloj Luigi , Mendichovszky Iosif , Hader Stefan , Boros Istvan , Brown Morris , Cheow Heok , Aigbirhio Franklin , Gurnell Mark

Background: Primary aldosteronism (PA) is an important, potentially curable, cause of hypertension. Distinguishing unilateral and bilateral causes is a critical step in determining who should be considered for adrenalectomy. Adrenal vein sampling (AVS) remains the gold standard for lateralisation. However, AVS is technically challenging with limited availability. To address this, we have introduced molecular imaging using PET/CT with the radiotracer [11C]Metomidate ...

ea0077op3.3 | Reproductive and Neuroendocrinology | SFEBES2021

‘Suppression imaging’ – a novel PET technique for increasing confidence in the localisation of secretory pituitary microadenomas

MacFarlane James , Kourlouri Olympia , Gillett Daniel , Senanayake Russell , Santarius Thomas , Tysome James , Donnelly Neil , Mendichovszky Iosif , Cheow Heok , Mannion Richard , Bashari Waiel , Gurnell Mark

Background: In a sub-group of patients with newly diagnosed pituitary adenomas, conventional MRI will fail to confidently localise the tumour. The role of molecular imaging for these patients is increasingly being recognised, both in terms of confirming diagnosis and in guiding targeted therapy; 11C-Methionine PET co-registered with volumetric MRI (Met-PET/MRCR) can enhance decision making in this group of patients. However, in some cases distinguishing t...

ea0065op6.1 | Neuroendocrinology, Pituitary and Neoplasia | SFEBES2019

Extended TSS (guided by 11C-methionine PET + MRI (Met-PET/MRCR)) can be an effective treatment option for patients with persistent acromegaly due to previously deemed unresectable lateral disease

Bashari Waiel A , Senanayake Russell , Fernandez-Pombo Antia , Gillett Daniel , Koulouri Olympia , Powlson Andrew , Cheow Heok , Mendichovszky Iosif , Kolias Angelos , Tysome James , Santarius Thomas , Mannion Richard , Gurnell Mark

Objective: To determine if an extended lateral approach to trans-sphenoidal surgery (TSS), guided by 11C-Methionine PET/CT co-registered with volumetric MRI (Met-PET/MRCR), can lead to remission in patients with persistent acromegaly due to post-operative lateral/para-sellar tumour remnants.Methods: We identified eight patients with persistent acromegaly following primary intervention [TSS ± medical therapy ± radiotherapy ...

ea0037gp.20.08 | Pituitary – Hypopituitarism | ECE2015

‘Pseudo-resistance' in macroprolactinomas treated with dopamine agonists; recognising delayed radiological response and a role for 11C-methionine PET-CT in guiding management

Powlson Andrew S , Koulouri Olympia , Steuwe Andrea , Gillett Daniel , Heard Sarah , Hoole Andrew , Scott Miriam , Challis Benjamin G , Antoun Nagui , Cheow Heok K , Mannion Richard J , Gurnell Mark

Background: Endocrine Society guidelines classify macroprolactinomas as ‘resistant’ if there is failure to normalise prolactin, or to achieve radiological tumour shrinkage of >50%, on standard doses of dopamine agonist. In this context, escalation of treatment to maximal tolerable doses and/or referral for surgery is advised. However, we have recently observed several ‘discordant responders’, where tumour shrinkage lags significantly (>6 months) beh...

ea0086oc3.1 | Reproductive and Neuroendocrinology | SFEBES2022

Depot somatostatin receptor ligand therapy reverses tissue thyrotoxicosis in thyrotropinomas and aids microadenoma localization via 11C-Methionine PET

Koulouri Olympia , MacFarlane James , Bashari Waiel , Gillett Daniel , Senanayake Russell , Halsall David , Oddy Sue , Powlson Andrew , Serban Laura , Moran Carla , Schoenmakers Nadia , Chatterjee Krishna , Gurnell Mark

Context: Surgery is the first-line treatment option for thyrotropinomas, but medical therapy with somatostatin receptor ligands (SRL) may be used as neoadjuvant treatment and to facilitate safe surgery.Objectives: To determine the extent to which neoadjuvant SRL (i) corrects clinical, laboratory and tissue hyperthyroidism in thyrotropinomas, (ii) induces tumour shrinkage in macroadenomas, and (iii) aids microadenoma detection by 11C-methionine...

ea0038p299 | Pituitary | SFEBES2015

A role for 11C-methionine PET/CT–MRI in the management of de novo and residual acromegaly

Koulouri Olympia , Hoole Andrew , Steuwe Andrea , Gillett Daniel , Powlson Andrew , Akker Scott , Aylwin Simon , Brooke Antonia , Buch Harit , Drake Will , Levy Miles , Siddiqi Ayesha , Simpson Helen , Chatterjee Krishna , Burnet Neil , Antoun Nagui , Cheow Heok , Mannion Richard , Pickard John , Gurnell Mark

Background: Although MRI remains the investigation of choice for pituitary imaging, it does not provide information about the ‘functionality’ of lesions (e.g. residual adenoma vs post-surgical scar tissue), and cannot reliably identify all microadenomas. These limitations are of particular relevance in acromegaly where clinical and biochemical evidence of disease activity mandates (further) treatment.Methods: We hypothesised that i) imaging wit...

ea0077oc4.3 | Adrenal and Cardiovascular | SFEBES2021

[11C]Metomidate PET/CT can aid decision-making in patients with primary aldosteronism

Senanayake Russell , Gillett Daniel , Ali Zahabia , Bashari Waiel , MacFarlane James , Koulouri Olympia , van der Meulen Merel , Powlson Andrew , Challis Benjamin , Palma August , Hu Lihua , Aloj Luigi , Mendichovszky Iosif , Cuthbertson Dan , Shore Susannah , Levy Miles , Drake William , Brown Morris , Kosmoliaptsis Vasilis , Marker Alison , Cheow Heok , Gurnell Mark

Background: Primary aldosteronism (PA) is the leading, potentially reversible, cause of secondary hypertension. For most patients in whom surgery is being considered, adrenal vein sampling (AVS) is recommended to distinguish unilateral and bilateral causes. However, AVS remains technically challenging, and a significant proportion of patients are unable to progress to surgery because AVS is unavailable or unsuccessful. We have explored whether [11C]Metomidate PET/CT...